Breakthrough rhino-orbito-cerebral mucormycosis caused by <i>Rhizopus arrhizus</i> during posaconazole prophylaxis after allogeneic hematopoietic stem cell transplantation: a case report and focused literature review. [PDF]
Qu J +5 more
europepmc +1 more source
The Brief Case: Recalcitrant cutaneous and subcutaneous knee infection caused by <i>Purpureocillium lilacinum</i>. [PDF]
Li M-C +6 more
europepmc +1 more source
Hepatotoxicity in hematologic malignancy and hematopoietic stem cell transplant patients receiving posaconazole or isavuconazole prophylaxis: a single-center cohort study. [PDF]
Steele S, Nichols C, Coe K, Tran N.
europepmc +1 more source
Refractory Invasive Pulmonary Aspergillosis Following Treatment of Acute Rejection in a Kidney Transplant Recipient: A Case Report. [PDF]
Aboukasm G +2 more
europepmc +1 more source
Physiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between vincristine and the azole antifungals isavuconazole, posaconazole, and voriconazole in children. [PDF]
Choules MP +5 more
europepmc +1 more source
Fosmanogepix Treatment for Coccidioidomycosis Under an Expanded Access Program. [PDF]
Cohen SH +11 more
europepmc +1 more source
Posaconazole mitigates α-amanitin-induced liver injury by inhibiting STT3B-mediated glycosylation and cellular uptake. [PDF]
Wang B +9 more
europepmc +1 more source
Cutaneous mucormycosis at the onset of type 1 diabetes in two pediatric patients. [PDF]
Thompson GM +12 more
europepmc +1 more source
Real-World Experience with Venetoclax Therapeutic Drug Monitoring in Acute Myeloid Leukemia: Role of Posaconazole, Correlation with Safety and Efficacy. [PDF]
Sani B +15 more
europepmc +1 more source
Subtherapeutic posaconazole exposure during delayed-release tablet prophylaxis in high-risk patients with haematological malignancies: rationale for routine therapeutic drug monitoring. [PDF]
Urbancic KF +11 more
europepmc +1 more source

